SCHEMBL773462

SCHEMBL773462

OCCn1ncc(-c2nc(-c3cc(F)ccc3F)no2)c1-c1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 11/20 0.76
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
MEN1 O00255 1/20 0.43
PKM P14618 1/20 0.43
NFKB1 P19838 1/20 0.43
MAPK1 P28482 1/20 0.43
NFKB2 Q00653 1/20 0.43
KMT2A Q03164 1/20 0.43
RELA Q04206 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAOA P21397 1/20 0.41
BLVRB P30043 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
PTGIR P43119 2/20 0.40
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL773443 0.90 S1PR1 (0.80) S1PR1NPC1RAB9AMEN1PKM
SCHEMBL15929388 0.88 S1PR1 (0.78) S1PR1NPC1RAB9AMEN1PKM
SCHEMBL772453 0.87 S1PR1 (1.00) S1PR1NPC1RAB9AMEN1PKM
SCHEMBL774522 0.84 S1PR1 (0.68) S1PR1NPC1RAB9AMEN1PKM
SCHEMBL772895 0.83 S1PR1 (0.72) S1PR1NPC1RAB9APKMKMT2A
SCHEMBL772797 0.83 S1PR1 (0.69) S1PR1NPC1RAB9AMEN1PKM
SCHEMBL798035 0.82 S1PR1 (1.00) S1PR1NPC1RAB9AMEN1KMT2A
SCHEMBL774088 0.82 S1PR1 (0.73) S1PR1NPC1RAB9APKMKMT2A
SCHEMBL773147 0.82 S1PR1 (1.00) S1PR1NPC1RAB9AMEN1PKM
SCHEMBL772500 0.81 S1PR1 (1.00) S1PR1NPC1RAB9AMEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440554-B1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2016-10-05 EP disclosed
US-8802663-B2 Pyrazole oxadiazole derivatives as S1P1 agonists MERCK SERONO SA (CH) 2014-08-12 US disclosed
EP-2440554-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS Merck Serono S.A. (CH) 2012-04-18 EP disclosed
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2012-03-22 US disclosed
WO-2010142628-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO S.A. (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS S1PR1, S1PR3, S1PR2 S1PR1 1/4885NPC1 734/4885RAB9A 3147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.